EN DE
Watch Beijing Water Business Doctor for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Beijing Water Business Doctor (300055) fair value: what the stock is really worth

As of Nov 6, 2026: fair value (intrinsic value) of Beijing Water Business Doctor stock ¥1.40, price ¥4.78, that is 70.7% below the price, quality 31 out of 100. Rating: strongly overvalued. Calculated from audited financials with 2 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Basic Materials CN · ISIN CNE100000LR6

BW Beijing Water Business Doctor logo Thin data Nov 7, 2026

Beijing Water Business Doctor

300055 · SHE
Very expensive, weak quality

Our calculation puts a fair price 71% below what the stock costs today.

Low debt
Expensive Growth (revenue 5y +32.9 %/yr in CNY)
0.3% dividend yield · Token dividend
Profit last quarter 49% below a year ago.
Fair value ¥1.40 · Strongly overvalued (−70.7%)
Quality 31/100
Loss-making · -8.7% net margin (TTM)
Negative free cash flow
Trails peers (2/13)
Narrow moat 12/100
Thin data
⟳ Cyclical
Watch Beijing Water Business Doctor for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

¥19.31 ¥3.77 Fair Value ¥1.40 May 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 7, 2026.

How to read this chart

60‑month range ¥3.77 – ¥19.31 · fair‑value band ¥0.5600 – ¥2.22 · the ¥4.78 price screens above the ¥1.40 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 7, 2026.

Follow Beijing Water Business Doctor in your weekly email

Every Wednesday you see whether Beijing Water Business Doctor is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Beijing WBD New Materials Group Co., Ltd. engages in water engineering and operation, hazardous and solid waste treatment, environmental protection, and equipment manufacturing businesses in China.

Show moreShow less

It operates through four segments: Industrial Water Treatment, Waste Treatment Services, Financial Investment, and Chemical Materials.

The company also offers isoprene, m-prene, dicyclopentadiene, carbon pentapet resin, and mixed xylene, which are used in rubber, elastomers, hot-melt adhesives, road sign paints, tires, pesticides and pharmaceutical intermediates, and other terminal application fields.

It serves large and medium-sized state-owned enterprises. The company was formerly known as Beijing Water Business Doctor Co., Ltd. and changed its name to Beijing WBD New Materials Group Co., Ltd. in May 2026. The company was founded in 1998 and is headquartered in Beijing, China.

Stock analysis

Beijing Water Business Doctor (300055) currently trades at ¥4.78, while our model-based Fair Value estimate is ¥1.40, 71% below the price, so the stock looks overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 2 models at a data quality of 88/100, which puts the data coverage at low.

Scenario range: ¥0.5600 (bear) to ¥2.22 (bull), the price of ¥4.78 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 31/100 (below-average quality), in the Basic Materials sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

Beijing Water Business Doctor reported revenue of 2.6B CNY in FY2025 versus 2.0B CNY in FY2021, a compound +6.8%/yr. Reported net income was −255M CNY in FY2025.

Key figures

Market cap 4.0B CNY (≈ $600M) Small · P/S ratio 1.47 · EPS (TTM) ¥−0.2800 · Dividend yield 0.3% · Net margin −8.7% · Return on equity −4.2% · Return on assets (EBIT) 0.6% (5-year average) · Operating margin 2.2%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 12 out of 100 (medium confidence).

What moves the price

The share trades about 62% below its 52-week high and 4% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Basic Materials peers we cover trades at −43% fair-value upside, at −71%, 300055 screens richer than that median.

Fair Value models

Bear ¥0.5600 Fair Value ¥1.40 Bull ¥2.22
Price ¥4.78 · Downside -70.7%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
EV/EBITDA ¥0.2800 ¥0.7000 ¥1.11 63
NCAV (Graham) ¥2.58 ¥3.45 ¥5.16 54
All 2 models by family
Multiples
EV/EBITDA ¥0.2800 ¥0.7000 ¥1.11 63
Asset-Based
NCAV (Graham) ¥2.58 ¥3.45 ¥5.16 54

The fair value above starts from this blend and is adjusted for a cyclical trough year.

Open the full fair value analysis →

Quality Score breakdown

Overall quality 31/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 6
How much profit the company makes from its sales and capital
Quality Growth 24
Are margins and returns getting better?
Cashflow 0
Do the profits arrive as real cash?
Financial strength 46
Debt, balance sheet and risk of trouble
Investment 59
Does it invest with discipline instead of growing at any price?
Low Volatility 62
How calm the share price moves, does not count
Price momentum 17
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 3
Distance to the 52-week high, does not count
New shares 75
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 32/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
−4.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−1.3%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+32.9%
Start year 2020 (pandemic). Over 10 years: +2.9% a year
Revenue growth 16 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+11.2%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
15.5% (2019) → −1.0% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

300055 screens overvalued: fair value 71% below the price. Compare with Linde plc →

Compare Beijing Water Business Doctor with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Specialty Chemicals · 727 stocks

Beats the industry median on 2/12 measures
Overall it trails its industry peers.
Valuation
Quality Score 31 · Bottom 25%
Fair Value upside −70.7% · Bottom 25%
Profitability
Return on assets −3.0% · Bottom 25%
Net margin (12 months) −8.7% · Bottom 25%
Operating margin (12 months) 2.2% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) 9.8% · Below median
Dividend yield (12 months) 0.3% · Bottom 25%
Balance sheet
Debt / equity 0.17× · Above median

Valuation Multiplesvs Specialty Chemicals median · lower = cheaper

P/B 0.82× · Cheapest 25%
P/S (12 months) 1.44× · Pricier than median
EV/EBITDA 60.5× · Priciest 25%
PEG 0.27× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 0
FUTURE (revenue growth)49 · sector 67
PAST (return on equity)0 · sector 26
HEALTH (low debt)91 · sector 95
DIVIDEND (yield)6 · sector 30

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Specialty Chemicals stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Nan Ya Plastics Corporation 1303 239.50 TWD 383.20 TWD +60% vs 300055
Wanhua Chemical Group 600309 ¥72.65 ¥68.03 −6% vs 300055
Linde plc LIN $515.25 $446.62 −13% vs 300055
PPG Industries, Inc PPG $122.38 $77.68 −37% vs 300055
DSM-Firmenich AG DSFIR CHF 100.50 CHF 57.70 −43% vs 300055
The Sherwin-Williams Company SHW $344.10 $146.37 −57% vs 300055
Givaudan SA GIVN CHF 4,054 CHF 1,554 −62% vs 300055
EMS-CHEMIE HOLDING AG EMSN CHF 848.50 CHF 284.63 −66% vs 300055
Ecolab Inc ECL $300.68 $96.56 −68% vs 300055
Air Products and Chemicals, Inc APD $304.84 $82.92 −73% vs 300055

Explore undervalued stocks

More undervalued Basic Materials stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Evidence & backtest34 years, failed companies included Financial calculatorsDCF, Graham, PEG and more
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Beijing Water Business Doctor: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Beijing Water Business Doctor Fair Value". https://www.fairvalue-calculator.com/stock/300055

Frequently asked questions

Is Beijing Water Business Doctor (300055) overvalued or undervalued?
As of Nov 7, 2026, our model estimates a fair value of ¥1.40 versus a price of ¥4.78, about 71% lower (overvalued).
What is the fair value of 300055?
Our model-based fair value for Beijing Water Business Doctor is ¥1.40 (as of Nov 7, 2026), built from audited fundamentals. The current price: ¥4.78.
What is the quality score of 300055?
Beijing Water Business Doctor has a Quality Score of 31/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Beijing Water Business Doctor (300055)?
Our model-based price target is the fair value of ¥1.40 (as of Nov 7, 2026) from 2 valuation models. Cautious scenario ¥0.5600, optimistic scenario ¥2.22. It is a calculation from audited fundamentals, not an analyst target.
What is the Beijing Water Business Doctor stock forecast for 2026?
Our models put fair value at ¥1.40, about 71% lower versus a price of ¥4.78 (overvalued). Cautious scenario ¥0.5600, optimistic scenario ¥2.22. The calculation is refreshed regularly with new filings.
What is the revenue of Beijing Water Business Doctor (300055)?
Beijing Water Business Doctor reported trailing-twelve-month revenue of about 2.8B CNY (latest available figure, as of Nov 7, 2026).
Does Beijing Water Business Doctor pay a dividend?
Beijing Water Business Doctor currently shows a dividend yield of 0.31% relative to its recent price (as of Nov 7, 2026).
How much is the dividend of Beijing Water Business Doctor (300055) and when is the ex-dividend date?
Beijing Water Business Doctor pays a dividend of ¥0.015 per share a year, a dividend yield of 0.3%. The last ex-dividend date was Jul 3, 2026. Our assessment: Token dividend. At a yield of 0.3% the dividend is symbolic. On paper it is not fully covered by earnings or free cash flow, but at this size that hardly matters: even scrapping it entirely would cost less than 0.3% a year, and coverage ratios on amounts this small swing with ordinary working-capital movements. Judge this company on its business, not on its dividend.
What is the intrinsic value of Beijing Water Business Doctor (300055)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Beijing Water Business Doctor it is ¥1.40 per share (as of Nov 7, 2026), against a price of ¥4.78. It is the blended result of 2 valuation models in 2 families (Multiples, Asset-Based).
Is Beijing Water Business Doctor stock overvalued or undervalued in 2026?
As of Nov 7, 2026, 300055 trades above its calculated fair value: price ¥4.78, fair value ¥1.40, a gap of about −71% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 300055?
No. The price is what the market pays today (¥4.78); the fair value is what the company's own numbers justify (¥1.40). For Beijing Water Business Doctor the two are ¥3.38 per share apart. That gap is exactly why we show both numbers side by side.
How much is Beijing Water Business Doctor worth?
The market values Beijing Water Business Doctor at about 4.0B CNY (market capitalisation, as of Nov 7, 2026). Per share that is ¥4.78; our models calculate a fair value of ¥1.40 per share.
What do the bullish and bearish scenarios say about 300055?
Our models span a range for Beijing Water Business Doctor: cautious scenario ¥0.5600, base ¥1.40, optimistic ¥2.22 per share (as of Nov 7, 2026, price ¥4.78). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the PEG ratio of 300055?
The PEG ratio of Beijing Water Business Doctor is 0.27 (P/E divided by earnings growth, as of Nov 7, 2026). That is below 1, so growth is priced more cheaply than the earnings multiple alone suggests.
How solid is the balance sheet of Beijing Water Business Doctor (300055)?
Balance-sheet figures for Beijing Water Business Doctor (as of Nov 7, 2026): return on equity −4.2%, debt of 0.17 per unit of equity. They feed the Quality Score of 31/100, which measures business quality independently of the share price.
How far is 300055 from its 52-week high?
Beijing Water Business Doctor trades at ¥4.78, about 62% below its 52-week high of ¥12.58 and 4% above the low of ¥4.61 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of ¥1.40 is for.
Which stocks are comparable to Beijing Water Business Doctor?
From the same area (Basic Materials) we also value Linde plc, Ecolab Inc, The Sherwin-Williams Company, Nan Ya Plastics Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Beijing Water Business Doctor stock attractive at the current price?
The data as of Nov 7, 2026: price ¥4.78, calculated fair value ¥1.40 (−71%), Quality Score 31/100, from 2 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 300055 calculated?
We run Beijing Water Business Doctor through 2 models from 2 families: Multiples, Asset-Based. Every model gets the same audited fundamentals; the fair value of ¥1.40 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0% above its aggregate fair value. Beijing Water Business Doctor itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Beijing Water Business Doctor (300055)?
The closing price on Nov 6, 2026 was ¥4.78. Our model-based fair value is ¥1.40, about 71% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Beijing Water Business Doctor right now?
The price sits above even our optimistic bull case (¥2.22). The favourable scenario is already priced in. Weak quality (31/100) and above fair value at the same time, the margin of safety is missing on both counts. The model range is unusually wide (¥0.5600 to ¥2.22). The outcome hinges heavily on assumptions, so read the point estimate with caution. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Key figures of Beijing Water Business Doctor

How large is the market capitalisation of Beijing Water Business Doctor (300055)?
The market capitalisation of Beijing Water Business Doctor is 4.0B CNY (≈ $600M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Beijing Water Business Doctor (300055)?
The price-to-sales ratio of Beijing Water Business Doctor is 1.47 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Beijing Water Business Doctor (300055)?
Earnings per share at Beijing Water Business Doctor are ¥−0.2800. Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Beijing Water Business Doctor (300055)?
The dividend yield of Beijing Water Business Doctor is 0.3%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Beijing Water Business Doctor (300055)?
The net margin of Beijing Water Business Doctor is −8.7% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Beijing Water Business Doctor (300055)?
The return on equity (ROE) of Beijing Water Business Doctor is −4.2% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Beijing Water Business Doctor (300055)?
On an EBIT basis the return on assets of Beijing Water Business Doctor is 0.6% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Beijing Water Business Doctor (300055)?
The operating margin of Beijing Water Business Doctor is 2.2% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Beijing Water Business Doctor (300055)?
Revenue at Beijing Water Business Doctor is growing +9.8% versus a year earlier (3y avg −1.3%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Beijing Water Business Doctor (300055)?
Earnings per share at Beijing Water Business Doctor are growing −49.0% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Beijing Water Business Doctor (300055) generate?
The free cash flow of Beijing Water Business Doctor is −810M CNY (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Beijing Water Business Doctor (300055) carry?
The net debt of Beijing Water Business Doctor is 806M CNY (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Beijing Water Business Doctor in the live analysis

One click puts Beijing Water Business Doctor on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.